Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial

Faster, Cleaner, Better.

Longevity Health Hldgs (XAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

Cash Flow for [[ item.sessionDateDisplayLong ]]

Fiscal Year End Date: 12/31

(Values in U.S. thousands)

	12-2024	12-2023	12-2022	12-2021	12-2017
Cash Flows From Operating Activities
Net Income	-10,651	-16,205	-9,051	-329	N/A
Depreciation Amortization	217	160	2,287	N/A	N/A
Accounts receivable	-4	N/A	N/A	N/A	N/A
Accounts payable and accrued liabilities	-359	-450	1,060	N/A	N/A
Other Working Capital	670	-3,422	2,339	16	N/A
Other Operating Activity	5,739	11,569	-63	-138	0
Operating Cash Flow	$-4,389	$-8,348	$-3,429	$-451	$N/A

Cash Flows From Investing Activities
PPE Investments	N/A	-31	-7	N/A	N/A
Net Acquisitions	-749	N/A	N/A	N/A	N/A
Purchase Of Investment	N/A	N/A	N/A	-154,441	N/A
Investing Cash Flow	$-749	$-31	$-7	$-154,441	$N/A

Cash Flows From Financing Activities
Debt Issued	496	1,860	2,746	57	N/A
Debt Repayment	-714	-3,202	N/A	-55	N/A
Common Stock Issued	2,687	41	146	159,080	N/A
Common Stock Repurchased	N/A	N/A	-2	N/A	N/A
Other Financing Activity	-86	12,464	662	-3,416	0
Financing Cash Flow	$2,382	$11,163	$3,552	$155,666	$N/A

Beginning Cash Position	2,913	128	12	N/A	N/A
End Cash Position	157	2,913	128	774	N/A
Net Cash Flow	$-2,755	$2,784	$116	$774	$N/A

Free Cash Flow
Operating Cash Flow	-4,389	-8,348	-3,429	-451	N/A
Capital Expenditure	N/A	-31	-7	N/A	N/A
Free Cash Flow	-4,389	-8,379	-3,436	-451	0